Reported about 11 hours ago
Novo Nordisk has agreed to acquire Akero Therapeutics for a total consideration of up to $5.2 billion in cash. The deal involves an initial payment of $54 per share, totaling $4.7 billion, and an additional contingent value of $6 per share, amounting to $500 million, contingent upon U.S. regulatory approval of Akero's liver disease drug, efruxifermin. This acquisition aligns with Novo's strategy to enhance its portfolio for treating diabetes and obesity-related conditions, and the transaction is expected to close by the end of the year.
Source: YAHOO